Conflict of interest statement:
N.H., Leukemia, R.T., AML, & Lymphoma, Celgene/Bristol, MaatPharma
ONCOLOGY, AML, LEUKEMIA
A.E.P. reports funding and other support from Astellas for this study; grants and contracts from AbbVie, Actinum Pharmaceuticals, Astellas, Daiichi Sankyo, Fujifilm, and Bayer; consulting fees from AbbVie, Astellas, Daiichi Sankyo, Forma Therapeutics, Sumitomo Dainippon Pharma, and Onconova; honoraria from Astellas and Daiichi Sankyo; and other financial support related to conference attendance and serving on advisory or data safety monitoring boards sponsored by Daiichi Sankyo, AbbVie, Astellas, Actinium, Celgene/Bristol-Myers Squibb, Genentech, Loxo, Syndax, Agios, Takeda, NewLink Genetics, and the Leukemia & Lymphoma Society/Beat AML, all outside the submitted work. R.A.L. reports funding and other support from Astellas for this study; grants or contracts from Cellectis, Forty Seven/Gilead Sciences, Rafael Pharmaceuticals, Novartis, and Daiichi Sankyo; consulting fees from Novartis, Agios, and CVS/Caremark; royalties from UpToDate; other financial support from Amgen and Novartis for conference attendance; and financial support for serving on data safety monitoring boards sponsored by Ariad/Takeda and Celgene/Bristol-Myers Squibb and on an external data review committee for Epizyme, all outside the submitted work. N.A.P. reports funding from Astellas for this study; consulting fees from Pfizer, Agios Pharmaceuticals, Blueprint Medicines, Incyte, Novartis, Celgene/Bristol-Myers Squibb, CTI BioPharma, PharmaEssentia, Constellation Pharmaceuticals, and AbbVie; and other financial support for serving on an independent data review committee for Cogent Biosciences, all outside the submitted work. S.S. reports other financial support for serving on advisory boards sponsored by AbbVie, Ber-GenBio, Astellas, Genentech, Kura Oncology, Novartis, Senti Bio, and Syros, all outside the submitted work. E.S.W. reports funding from Astellas for this study; consulting fees from Mana Therapeutics; honoraria from Stemline Therapeutics, Kura Oncology, Pfizer, and Dava Oncology; other financial support for serving on advisory boards sponsored by AbbVie, Astellas, Celgene/Bristol-Myers Squibb, Genentech, Gilead Sciences, GlaxoSmithKline, Jazz, Kite, Kura Oncology, Novartis, Pfizer, Stemline Therapeutics, and Takeda; and financial support for serving on data monitoring committees for AbbVie and Rafael Pharmaceuticals, all outside the submitted work. E.A. reports grants or contracts from Novartis and Takeda; other financial support for serving on advisory boards sponsored by Novartis, Takeda, Syndax, Bristol-Myers Squibb, AbbVie, Adaptive Biotechnologies, and Amgen; and other financial support for serving on advisory boards sponsored by AbbVie, Amgen, and Syndax and a data safety monitoring board sponsored by Takeda; and medical writing support from Novartis, all outside the submitted work. G.J.S. reports funding from Astellas for this study and honoraria from Astellas outside the submitted work. J.S. reports funding from Astellas for this study and honoraria for participation in a speaker program sponsored by Astellas, grant funding from Novartis, as well as personal fees from Astellas, Jazz, AbbVie, Daiichi Sankyo, Pfizer, and Novartis, all outside the submitted work. G.M. reports funding from Astellas for this study. P.M. reports funding from Astellas for this study and for the development of this manuscript and other grant funding from Astellas outside the submitted work. C.R. reports grants or contracts from AbbVie, Amgen, Novartis, Celgene/Bristol-Myers Squibb, Jazz, Agios, Daiichi Sankyo, Astellas, Sunesis, Roche, and MaatPharma; consulting fees from AbbVie, Jazz, Novartis, and Celgene/Bristol Myers-Squibb; honoraria from Astellas; and other financial support from Novartis, Gilead, Sanofi, Jazz, Amgen, and Daiichi Sankyo for travel/conference attendance, all outside the submitted work. S.S.Y. reports research grants from Roche-Genentech, Kyowa Kirin, and Yuhan Pharmaceuticals, as well as funding for participation on advisory boards sponsored by Amgen, Astellas, Celgene, Janssen, Novartis, and Takeda, all outside the submitted work. Y.M. reports funding from Astellas for this study and research funding from Astellas outside the submitted work. T.K. reports funding from Astellas for this study. H.J.K. reports honoraria and consultancy fees from Amgen, Astellas, Celgene/Bristol-Myers Squibb, Daiichi Sankyo, Novartis, Janssen, SL VaxiGen, and Yuhan Pharma; honoraria from AbbVie; and research funding from BL&H Co Ltd., all outside the submitted work. M.J.L. reports funding from Astellas for this study; research grants from Astellas and FujiFilm; and honoraria from Amgen, AbbVie, Astellas, Daiichi Sankyo, Bristol-Myers Squibb, Pfizer, Menarini, and Takeda, all outside the submitted work. N.H. and R.N. are employees of Astellas. R.T. is a former employee of Astellas. A.N., M.O., and N.H. have no conflicts of interest to report.